A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: A Japanese experience

Surgery Today

Volumn 41, Issue 12, 2011, Pages 1610-1616

  Baba, Hideo ^a   Hayashi, Naoko ^a   Emi, Yasunori ^b   Kakeji, Yoshihiro ^b   Egashira, Akinori ^b   Oki, Eiji ^b   Shirabe, Ken ^b   Toyama, Tetsuo ^c   Ohga, Takefumi ^d   Yamamoto, Manabu ^e   Hasegawa, Hirofumi ^f   Kohakura, Fumiko ^g   Higashi, Hidefumi ^h   Niwa, Kiyoshi ⁱ   Fujita, Fumihiko ^j   Ogata, Yutaka ^k   Kohnoe, Shunji ^l   Inomata, Masafumi ^m   Samura, Hironori ⁿ   Tokunaga, Shoji ^o   Maehara, Yoshihiko ^b   more..

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c Nakagami Hospital   (Japan)

^d SAISEIKAI FUKUOKA GENERAL HOSPITAL   (Japan)

^e ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^f Kyushu Center Hospital of the Mutual Aid Association of Public School Teachers   (Japan)

^g Urasoe General Hospital   (Japan)

^h STEEL MEMORIAL YAWATA HOSPITAL   (Japan)

ⁱ Sameshima Hospital   (Japan)

^j NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^k KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l FUKUOKA DENTAL COLLEGE   (Japan)

^m OITA UNIVERSITY   (Japan)

ⁿ UNIVERSITY OF THE RYUKYUS   (Japan)

^o KYUSHU UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Colorectal cancer; First line chemotherapy; FOLFOX4; Oxaliplatin

Indexed keywords

FLUOROURACIL; LEVOLEUCOVORIN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERPIGMENTATION; INFECTION; JAPANESE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; JAPAN; LEUCOVORIN; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES;

EID: 84855238496     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-4589-9     Document Type: Article

References (19)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Glimelius B, Hoffman K, Graf W, Pahlman L, Sjoden PO. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Cancer 1994;73:556-62. (Pubitemid 24046593)
3. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fl uorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18. (Pubitemid 19245110)
4. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fl uorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy. Lancet 1997;350:681-6. (Pubitemid 27371165)
5. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fl uorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18:136-47. (Pubitemid 30036347)
6. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fl uorouracil compared with fl uorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000; 355:1041-7. (Pubitemid 30162806)
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al. Leucovorin and fl uorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-47. (Pubitemid 30644117)
8. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, et al. A randomized controlled trial of fl uorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30. (Pubitemid 41095110)
9. Raymond E, Buquet-Fagot C, Djelloul S, Mester J, Cvitkovic E, Allain P, et al. Antitumor activity of oxaliplatin in combination with 5-fl uorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anticancer Drugs 1997;8:876-85. (Pubitemid 27487802)
10. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE c3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81. (Pubitemid 36962641)
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
12. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GECOR study. J Clin Oncol 2004;22:229-37. (Pubitemid 41095086)
13. Nagata N, Kondo K, Kato T, Shibata Y, Okuyama Y, Ikenaga M, et al. Multicenter phase II study of FOLFOX for metastatic colorectal cancer (mCRC) in Japan; SWIFT-1 and 2 study. Hepato-gastroenterology 2009;56:1346-53.
14. Grothey A, Sargent D. Overall survival of patients with advanced colorectal cancer correlates with availability of fl uorouracil, irinotecan, and oxaliplatin regardless of whether doublet or singleagent therapy is used first-line. J Clin Oncol 2005;23:9441-2.
15. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fl uorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209-14. (Pubitemid 41079833)
16. Tournigand C, Maindrault-Goebel F, Louvert C, de Gramont A, Krulik M. Severe anaphylactic reactions to oxaliplatin. Eur J Cancer 1998;34:1297-8.
17. Larzilliere I, Brandissou S, Breton P, Lingoungou A, Gargot D, Ramain JP, et al. Anaphylactic reaction to oxaliplatin: a case report. Am J Gastroenterol 1999;94:3387-8.
18. Medioni J, Coulon MA, Morere JF, Hennebelle F, Piperno-Neumann S, Breau JL. Anaphylaxis after oxaliplatin. Ann Oncol 1999;10:610.
19. Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003;89:477-81. (Pubitemid 37026428)